Case Introduction This case study focuses Burroughs Wellcome and their drug Retrovir. Retrovir is a drug that treats AIDS and AID-related complications. In 1987, Burroughs Wellcome obtained approval from the FDA to market azidothymidine (AZT), also known as Retrovir, as a treatment for AIDS. Retrovir was the only kind of drug on the market. Because of this, many critics accused Burroughs Wellcome of price-gouging, as the price of Retrovir was $188 for a hundred 100mg capsules sold to wholesalers
price of the Retrovir product. This was followed by the negative reaction from the management team to reduce the price of the drug. There are three possible alternatives to fix the problem: 1. Maintain status quo This alternative implies that Burroughs will maintain current prices unaltered. The company would have to invest more in marketing programs in order to communicate this to its customers. The government and nonprofit organizations already cut the price by 20% in 1987 and 1989. Also the
Addendum to Making the Right Moves: A Practical Guide to Scientific Management for Postdocs and New Faculty second edition Burroughs Wellcome Fund Howard Hughes Medical Institute Making the Right Moves: A Practical Guide to Scientific Management for Postdocs and New Faculty, second edition © 2006 by the Howard Hughes Medical Institute and Burroughs Wellcome Fund All rights reserved. “Writing a Letter of Recommendation”: Electronic addendum published 2009 Writer: Laura Bonetta, Ph.D. Production:
SALES MANAGEMENT Term Report On “Sales Training At GlaxoSmithKline” Submission Date 17th December’ 2012 Institute of Business Management – IoBM Letter of Acknowledgement We would like to express our whole hearted thanks to Almighty Allah by whose grace and blessings we have the knowledge; insight and opportunity to this complete this report. Most importantly, we are grateful to our instructor, , whose continuous support, faith and cooperation
CASE STUDY: SENSODYNE OVERTAKES COLGATE IN SENSITIVE CATEGORY INTRODUCTION The sensitive toothpaste segment accounts for less than 10% of the country 's Rs 5,400-crore toothpaste market at Rs 470 crore, but is growing at 50% a year. Oral care giant Colgate Palmolive, which controls about 53% of the country 's toothpaste market, has been selling its Sensitive brand in India since the last seven years. India had very low levels of awareness on the condition of tooth sensitivity. Over the past
Case Analysis - "Merck-Medco" Maureen Hergert MGT 362 - SPRING 2004 Professor Steven Francis Case Analysis - "MerckMedco" March 7, 2004 Introduction. Merck & Company (Merck) was a pharmaceutical researcher and manufacturer while Medco Cost Containment Services, Inc. (Medco) was a pharmacy benefit manager (PBM). On November 18, 1993, Merck purchased Medco for $6.6 billion. Immediately after the merger, Medco operated as a subsidiary of Merck. In 1994, MerckMedco was formed. 2 Grant states that corporate
For the exclusive use of S. Liu Harvard Business School 9-200-033 Rev. October 6, 2000 Kendle International Inc. We looked at the competitive landscape and, based on what was happening, knew we were either going to sell Kendle, grow or disappear. It was May 1997, and Candace Kendle, the chairman and chief executive officer of Kendle International Inc. (Kendle), and her husband Christopher C. Bergen, the president and chief operating officer, were reviewing the strategic options for